In the UK, the first world clinical examination of vaccines that should not be kept in the refrigerator, which could greatly increase global access to vaccination.
Vaccine against tetanus and diphtheria (SPVX02) The company stablepharma is completely stable at room temperature, and the company behind it says that with their advanced technology to produce up to 60 other types of vaccines.
The first examination of the vaccine on humans takes place in the Clinical Research Center of the National Institute for Health and Care (NIHR) in Southampton at Southampton University Hospital.
One of the biggest obstacles to the vaccination of people in some parts of the world is the “cold chain” needed to maintain the water vaccines from production to the injection site.
The World Health Organization (WHO) estimates that up to half vaccines are dropped in the world a year – mainly due to the lack of temperature control and logistics required to support an uninterrupted cold chain.
“This could be the right turning point”
The British Biotechnology Firma StablePharma showed that it can convert an existing approved vaccine to versions that can be kept at room temperature for a long time.
The British Minister of Health and Social Welfare Wes Streeting said, the vaccine was restrained in the need to be kept in the refrigerator – which caused endless amounts of waste and made their delivery to remote communities. “
“But thanks to the vision of this government and our investment through the National Institute of Health and Care, it could all change this by the initiative by encouraging the first world examination of vaccines without fridge. This could be the right turning point and salvation on a global scale.”
The test is expected to be completed this summer, and the results published by the end of the year.
StablePharma hopes that a new vaccine will be in use globally by 2027. years.
(Vijesti.ba)
